Theodore R Schroeder
CIK 1378690 · Chief Executive Officer · last filed 2026-05-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$871.1K
Companies
9
Total Filings
122
Lifetime Open-Market Net
-$1.41M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PHAT | Director | 45,122 | $10.37 | $467.9K | $0 | 2 | 2026-05-21 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | — | $221.38 | — | $0 | 13 | 2026-01-07 |
| Nabriva Therapeutics plc (NBRV) Delisted | Chief Executive Officer | 129,478 | $1.42 | $183.9K | $203.3K | 68 | 2023-01-31 |
| OTONOMY, INC. (OTIC) Delisted | Director | — | $0.08 | — | $0 | 8 | 2022-06-23 |
| COLL | Director | 11,007 | $34.64 | $381.3K | $0 | 2 | 2020-05-22 |
| ESPR | Director | 6,960 | $3.15 | $21.9K | $0 | 4 | 2019-04-29 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 0 | — | — | $0 | 2 | 2015-05-08 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | President, CEO | 320,164 | — | — | -$1.61M | 17 | 2014-02-12 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | — | — | — | $0 | 4 | 2013-05-23 |
Recent Filings · Page 2 of 13
122 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-12-08 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −9 | -$18 | EDGAR |
| 2022-12-02 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −5 | -$11 | EDGAR |
| 2022-11-08 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −10 | -$22 | EDGAR |
| 2022-11-01 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −5 | -$13 | EDGAR |
| 2022-10-11 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −9 | -$24 | EDGAR |
| 2022-10-04 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −5 | -$10 | EDGAR |
| 2022-09-07 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −225 | -$35 | EDGAR |
| 2022-09-01 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −107 | -$18 | EDGAR |
| 2022-08-15 | Nabriva Therapeutics plc (NBRV) Delisted | Exer (M) | — | $0 | EDGAR |
| 2022-08-08 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −225 | -$42 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.